JAK2 and myeloproliferative disorder: Gain-of-function (GOF) mutations in JAK1 and JAK3 are associated with leukaemia and lymphoma [7], while GOF mutations in JAK2 are highly associated with myeloproliferative disease including polycythemia vera, essential thrombocytopenia, and primary myelofibrosis [11].